Modality
Cell Therapy
MOA
GLP-1ag
Target
FcRn
Pathway
RAS/MAPK
Heart FailureACCRSV
Development Pipeline
Preclinical
~Apr 2023
→ ~Jul 2024
Phase 1
Oct 2024
→ Nov 2028
Phase 1Current
NCT06986517
1,468 pts·RSV
2024-10→2028-11·Terminated
1,468 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-052.6y awayInterim· RSV
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Termina…
Catalysts
Interim
2028-11-05 · 2.6y away
RSV
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06986517 | Phase 1 | RSV | Terminated | 1468 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn |